No black box warning on record for Pomalidomide

As of the latest FDA labeling reviewed, Pomalidomide (POMALIDOMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pomalidomide medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue ( 5.4 ). Hematologic Toxicity: Neutropenia was the most frequently reported Grade 3/4 adverse event. Monitor patients for hematologic toxicities, especially neutropenia ( 5.5 ). Hepatotoxicity: Hepatic failure including fatalities; monitor liver func

No black box warning on record for Pomalidomide

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue ( 5.4 ). Hematologic Toxicity: Neutropenia was the most frequently reported Grade 3/4 adverse event. Monitor patients for hematologic toxicities, especially neutropenia ( 5.5 ). Hepatotoxicity: Hepatic failure including fatalities; monitor liver func

Pomalidomide Black Box Warning

No black box warning on record for Pomalidomide

Other warnings & precautions

Pomalidomide Black Box Warning

No black box warning on record for Pomalidomide

Other warnings & precautions